Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Recorded changes
86,510 on record
Recorded policy changes, newest first| Recorded | Payer | Policy | Change |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Heterozygous Familial HypercholesterolemiaPayerPolicy · CAPBLUE-MP-2.363 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Hereditary PancreatitisPayerPolicy · CAPBLUE-MP-2.318 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Hereditary HemochromatosisPayerPolicy · CAPBLUE-MP-2.312 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Hereditary Hearing LossPayerPolicy · CAPBLUE-MP-2.319 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Helicobacter Pylori TreatmentPayerPolicy · CAPBLUE-MP-2.308 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Fanconi AnemiaPayerPolicy · CAPBLUE-MP-2.362 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Familial Cutaneous Malignant MelanomaPayerPolicy · CAPBLUE-MP-2.246 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Facioscpulohumeral Muscular DystrophyPayerPolicy · CAPBLUE-MP-2.321 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for FLT3, NPM1 and CEBPA Variants in Cytogenetically Normal Acute Myeloid LeukemiaPayerPolicy · CAPBLUE-MP-2.357 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for EpilepsyPayerPolicy · CAPBLUE-MP-2.262 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Duchenne and Becker Muscular DystrophyPayerPolicy · CAPBLUE-MP-2.257 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Diagnosis and Management of Mental Health ConditionsPayerPolicy · CAPBLUE-MP-2.264 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for DD, ID, Autism Spectrum Disorder and CAPayerPolicy · CAPBLUE-MP-2.242 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Cardiac Ion ChannelopathiesPayerPolicy · CAPBLUE-MP-2.233 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for CHARGE SyndromePayerPolicy · CAPBLUE-MP-2.322 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Alzheimer Disease (Formerly Diagnostic Testing and Risk Assessment for Alzheimer Disease)PayerPolicy · CAPBLUE-MP-2.050 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Alpha-1 Antitrypsin DeficiencyPayerPolicy · CAPBLUE-MP-2.251 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Alpha ThalassemiaPayerPolicy · CAPBLUE-MP-2.320 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Cancer Susceptibility Panels Using Next Generational SequencingPayerPolicy · CAPBLUE-MP-2.325 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate CancerPayerPolicy · CAPBLUE-MP-2.280 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | General Approach to Evaluating the Utility of Genetic PanelsPayerPolicy · CAPBLUE-MP-2.323 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Gene Expression Profiling for Uveal MelanomaPayerPolicy · CAPBLUE-MP-2.360 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Gene Expression Profiling for Cutaneous MelanomaPayerPolicy · CAPBLUE-MP-2.396 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Gene Expression Profiling, Protein Biomarkers, and Multimodal Artificial Intelligence for Prostate Cancer ManagementPayerPolicy · CAPBLUE-MP-2.263 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Gene Expression Profile Testing and Circulating Tumor DNA testing for Predicting Recurrence in Colon CancerPayerPolicy · CAPBLUE-MP-2.315 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Gene Expression Based Assays for Cancers of Unknown PrimaryPayerPolicy · CAPBLUE-MP-2.245 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Gender Affirming SurgeryPayerPolicy · CAPBLUE-MP-1.144 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Gastric Electrical StimulationPayerPolicy · CAPBLUE-MP-2.069 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Gas Permeable Scleral Contact Lens and Therapeutic Soft Contact LensPayerPolicy · CAPBLUE-MP-6.031 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Ganglion Impar BlockPayerPolicy · CAPBLUE-MP-2.378 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Foot Orthotics and Other Podiatric AppliancesPayerPolicy · CAPBLUE-MP-6.028 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Foot Care ServicesPayerPolicy · CAPBLUE-MP-2.018 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Facet Joint Injections and Medal Branch BlocksPayerPolicy · CAPBLUE-MP-4.050 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Facet Joint DenervationPayerPolicy · CAPBLUE-MP-5.049 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Extracorporeal Shock Wave Treatment for Plantar Fasciitis and Other Musculoskeletal ConditionsPayerPolicy · CAPBLUE-MP-2.034 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Extracorporeal PhotopheresisPayerPolicy · CAPBLUE-MP-2.068 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | External Infusion Pumps for Insulin Delivery and Automated Insulin Delivery SystemsPayerPolicy · CAPBLUE-MP-6.007 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Experimental and Investigational ProceduresPayerPolicy · CAPBLUE-MP-4.002 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Expanded AccessPayerPolicy · CAPBLUE-MP-2.386 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Evoked Potential StudiesPayerPolicy · CAPBLUE-MP-4.029 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Evaluation of Biomarkers for Alzheimer's DiseasePayerPolicy · CAPBLUE-MP-2.391 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Esophageal pH MonitoringPayerPolicy · CAPBLUE-MP-2.017 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Esketamine (Spravato)PayerPolicy · CAPBLUE-MP-2.367 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Epidural Steroid Injections for Back PainPayerPolicy · CAPBLUE-MP-4.014 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Enteral NutritionPayerPolicy · CAPBLUE-MP-2.015 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Endovascular Stent Grafts for Disorders of the Thoracic AortaPayerPolicy · CAPBLUE-MP-1.132 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Endovascular Grafts for Abdominal Aortic AneurysmPayerPolicy · CAPBLUE-MP-1.090 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Endoscopic Radiofrequency Ablation or Cryoablation for Barrett's EsophagusPayerPolicy · CAPBLUE-MP-1.118 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Endometrial AblationPayerPolicy · CAPBLUE-MP-7.013 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Electromyography and Nerve Conduction StudiesPayerPolicy · CAPBLUE-MP-2.063 | Criteria changed |
|---|